Intellisphere launches

Intellisphere launched an oncology news and information site——on March 15, and changed the title of its Oncology Net Guide print journal to OncLive.
The move represents an integration of the website with the print journal, said Peter Ciszewski, president, oncology specialty group, at Intellisphere. “Instead of having our writers write for the publication, they're writing for the web...constantly,” said Ciszewski. “We're going to use our website to see which articles the docs are reading most often, and then those articles will be expanded features within the publication.”
The March issue was mailed out as OncLive, and the journal will retain its net guide resource, which directs oncologists to cancer-related internet offerings. Ciszewski said the journal was among the top 10 oncology journals, in terms of advertising pages, last year. The rebrand helps the journal “stay ahead of the curve,” said Ciszewski. The March issue was mailed to “over 20,000 cancer professionals,” including medical oncologists and a core audience of hematologist-oncologists, plus radiology oncologists, surgical oncologists, and cancer-treating urologists, according to Ciszewski.
At, physicians can click on links for free CME offerings provided by Intellisphere sister company ArcMesa, as well as other CME houses. The site will also feature short video interviews with oncology thought leaders, about new data and studies in the field, said Ciszewski. “Oncologists want to see other oncologists talk about the data,” he said. Video interviews will be taped at medical conferences, and will be conducted with physicians at the Hackensack University Medical Clinic's John Theurer Cancer Center. At press time, a beta version of the site featured interviews with professors, physicians, and industry (Peter Langmuir, executive director of medical science at AstraZeneca), done at last summer's ASCO meeting.
You must be a registered member of MMM to post a comment.

Next Article in Features

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters

Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.